

Texas Department of State
Health Services

Respiratory Syncytial Virus (RSV) Surveillance

Diana Martínez, PhD, MPH
Deputy State Epidemiologist
Office of the Chief State Epidemiologist
Texas Department of State Health Services
October 30, 2023

DISCLAIMER

The information presented today is based in current preliminary data and on CDC's recent guidance. Information is subject to change.

October 30, 2023



Texas Department of State Health Services

RSV Surveillance & Seasonality

RSV Surveillance U.S.




Texas Department of State Health Services

- National Respiratory and Enteric Virus Surveillance System (NRVESS) for monitoring RSV surveillance
- NRVESS is a passive laboratory-based surveillance
 - Voluntary reporting by participating commercial, hospital, and state/local public health laboratories
 - ~300 laboratories report RSV results
 - Weekly reporting of total tests performed and RSV positive tests
- All test types (majority PCR assays)
- Testing is clinician-directed
- All ages




Source: National Respiratory and Enteric Virus Surveillance System | CDC accessed 10/6/2023

During 2011-2020, RSV circulation was highly seasonal in the U.S. with predictable peak activity during December – February annually



Source: CDC RSV ACIP Meeting accessed 10/6/2023

Changes in RSV Seasonality in the U.S., 2017-2023





Texas Department of State Health Services


RSV in Texas

RSV in Texas




Texas Department of State Health Services

- Three different data sources to estimate RSV seasonality and RSV disease burden in Texas
 - 1. NREVSS
 - 2. Syndromic Surveillance (TxS2)
 - Emergency department data from about 80% of all hospitals reporting real time (every 4 to 24 hours)
 - 3. Hospitalization Data
 - Texas Health Care Information Collection (THCIC) inpatient research data file
 - Hospital discharge data from all hospitals
 - Data lag of 6 9 months




RSV in Texas, July 2018 – September 2023 NRVESS






Source: National Respiratory and Enteric Virus Surveillance System (NREVSS), July 2018 September 2023. Data were extracted October 24, 2023.

Number & Percentage of PCR Tests Positive for Respiratory Syncytial Virus (RSV) All Texas Sites, 2023-2024 Season




RSV in Texas, 2020 – 2023, All Age Groups Syndromic Surveillance






RSV in Texas, 2020 – 2023, Under 5 Years of Age Syndromic Surveillance





RSV in Texas, 2022 – 2023, Under 5 Years of Age Syndromic Surveillance






Source: Texas Syndromic Surveillance (TxS2). Data were extracted September 28, 2023.


RSV in Texas, 2021 – 2023, by Age Groups Syndromic Surveillance





RSV in Texas, 2021 – 2023, <u>>50</u> years of age Syndromic Surveillance






RSV Seasonality Estimates In Texas, 2017-2023 (Syndromic Surveillance)



RSV Seasonality Estimates in Texas, 2019-2020 (Laboratory, Syndromic, and Hospital Data)





Texas Department of State Health Services

RSV Disease Burden

RSV is the leading cause of hospitalization in U.S. Infants

Source: CDC RSV ACIP Meeting accessed 10/6/2023

- Most (68%) infants are infected in the first year of life and nearly all (97%) by age 2¹
- Premature infants born at <30 weeks gestation had hospitalization rates ~3x higher than term infants²
 - Preterm infants have higher rates of ICU admission, mechanical ventilation³
 - Average cost of hospitalization in infant <29 weeks ~4x higher than for term infant³
- 79% of children hospitalized with RSV aged <2 years had no underlying medical conditions²
- 2-3% of all infants will be hospitalized for RSV^{2,4}



Image: Goncalves et al. Critical Care Research and Practice 2012

Each year in U.S. children aged less than 5 years, RSV is associated with...

100-300^{1,2} deaths

58,000-80,000^{3,4} hospitalizations

~520,000³ emergency department visits

~1,500,000³ outpatient visits

MMWR: RSV hospitalizations have worse clinical outcomes for older adults than flu, COVID in the U.S.

TABLE 2. In-hospital outcomes among adults aged ≥60 years hospitalized with respiratory syncytial virus, COVID-19, or influenza — Investigating Respiratory Viruses in the Acutely III Network, 25 hospitals,* 20 U.S. states, February 1, 2022–May 31, 2023

In-hospital outcomes	No./Total no. (%)						
	RSV patients n = 304	COVID-19 patients n = 4734	Influenza patients n = 746	RSV vs. COVID-19 aOR [†] (95% CI)	p-value	RSV vs. influenza aOR† (95% CI)	p-value
Standard flow oxygen therapy [§]	157/197 (79.7)	2,169/3,726 (58.2)	390/593 (65.8)	2.97 (2.07-4.27)	<0.001	2.07 (1.37–3.11)	<0.001
HFNC or NIV¶	59/256 (23.0)	495/4,223 (11.7)	94/687 (13.7)	2.25 (1.65–3.07)	<0.001	1.99 (1.36–2.90)	<0.001
ICU admission	74/304 (24.3)	819/4,734 (17.3)	125/746 (16.8)	1.49 (1.13–1.97)	0.005	1.55 (1.11–2.19)	0.01
IMV or death	41/304 (13.5)	481/4,734 (10.2)	52/746 (7.0)	1.39 (0.98–1.96)	0.07	2.08 (1.33–3.26)	0.001

Abbreviations: aOR = adjusted odds ratio; HFNC = high-flow nasal cannula; ICU = intensive care unit; IMV = invasive mechanical ventilation; NIV = noninvasive ventilation; RSV = respiratory syncytial virus.

^{*} https://www.cdc.gov/flu/vaccines-work/ivy.htm


^{*} Multivariable logistic regression models were adjusted for age, sex, race and ethnicity, number of organ systems with chronic medical conditions, and U.S. Department of Health and Human Services region.

[§] Standard flow oxygen therapy was defined as receipt of supplemental oxygen therapy at a flow rate <30 L/minute as the highest level of oxygen support received during hospitalization.

[¶] HFNC or NIV was defined as patients who received either HFNC (oxygen therapy at a flow rate ≥30 L/minute) or NIV as the highest level of oxygen support received during hospitalization.


RSV Hospitalizations in Texas, 2020 – 2022 By Age Groups, THCIC





RSV Hospitalizations in Texas Among Persons <5yrs, 2020 – 2022, THCIC





Overall Summary of RSV Hospitalizations in Texas January 2020 - December 2022

Of all RSV hospitalizations in TX, 88% were in children < 5 years of age

63% did not have underlying medical conditions

Among children less than 5 yrs, **87% of RSV**hospitalizations were in children < 1 year of age</p>

Among children less than 5 yrs, 45% of RSV hospitalizations were in children 0-5 months of age

Overall Summary of RSV Hospitalizations in Texas January 2020 - December 2022

Of all RSV hospitalizations, 45% were admitted to the ICU

Among all ICU admissions, 89% of ICU admissions were in children < 5 years of age

Among ICU admissions for children < 5 yrs, **88% were in children < 1** year of age

Next Steps



- Further develop analysis of RSV burden in Texas
 - Include data from 2017 to 2022
 - Compare RSV rates Pre and post COVID-19 Pandemic
- Enhance the surveillance of respiratory viruses
 - Work with health systems to expand voluntary reporting of respiratory virus laboratory results
 - Recruit additional laboratories to submit to NREVSS





- Anna Klioueva
- Erica Mendoza
- Lisa Landry
- Sarah Stick*
- Emilio Gonzalez

*formerly at DSHS



Texas Department of State Health Services

Thank you